Key Points
- Arthur Butcher sold 17,313 Boston Scientific shares at an average price of $101.55 on Dec. 1 for a total of $1,758,135.15, cutting his ownership by 42.32% to 23,600 shares (about $2.40M).
- Company performance and outlook: Boston Scientific beat Q3 estimates with $0.75 EPS and $5.07B revenue (revenue +20.3% y/y), set FY2025 guidance of $3.020–3.040 EPS, and holds a consensus "Buy" rating with an average target of $123.77.
Boston Scientific Corporation (NYSE:BSX - Get Free Report) EVP Arthur Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Boston Scientific Price Performance
Shares of NYSE:BSX opened at $99.03 on Wednesday. The firm has a market capitalization of $146.80 billion, a price-to-earnings ratio of 52.96, a price-to-earnings-growth ratio of 2.03 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The business's 50 day simple moving average is $99.28 and its 200-day simple moving average is $102.19. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50.
Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.Boston Scientific's quarterly revenue was up 20.3% on a year-over-year basis. During the same period last year, the business posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the company. Evercore ISI reaffirmed an "outperform" rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. UBS Group lifted their target price on shares of Boston Scientific from $135.00 to $140.00 and gave the stock a "buy" rating in a research report on Thursday, October 23rd. Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and upped their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. The Goldman Sachs Group reissued a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 22nd. Finally, Needham & Company LLC restated a "buy" rating and set a $121.00 price objective on shares of Boston Scientific in a research report on Friday, October 17th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $123.77.
View Our Latest Research Report on BSX
Hedge Funds Weigh In On Boston Scientific
Institutional investors have recently modified their holdings of the company. Riverwater Partners LLC boosted its position in Boston Scientific by 3.3% during the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider's stock worth $333,000 after acquiring an additional 98 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management raised its holdings in Boston Scientific by 3.8% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider's stock valued at $291,000 after acquiring an additional 99 shares during the last quarter. Crown Wealth Group LLC lifted its stake in shares of Boston Scientific by 4.7% during the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider's stock worth $218,000 after purchasing an additional 100 shares during the period. IVC Wealth Advisors LLC boosted its holdings in shares of Boston Scientific by 4.9% during the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider's stock worth $236,000 after purchasing an additional 102 shares during the last quarter. Finally, Claret Asset Management Corp boosted its holdings in shares of Boston Scientific by 4.4% during the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider's stock worth $234,000 after purchasing an additional 102 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.
About Boston Scientific
(
Get Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
